Natixis Advisors LLC Lowers Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Natixis Advisors LLC lowered its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 53.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 23,506 shares of the biopharmaceutical company's stock after selling 27,404 shares during the quarter. Natixis Advisors LLC's holdings in Ultragenyx Pharmaceutical were worth $851,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Federated Hermes Inc. grew its stake in shares of Ultragenyx Pharmaceutical by 0.3% in the 1st quarter. Federated Hermes Inc. now owns 2,055,200 shares of the biopharmaceutical company's stock valued at $74,419,000 after purchasing an additional 5,400 shares during the period. Invesco Ltd. grew its stake in shares of Ultragenyx Pharmaceutical by 1.5% in the 4th quarter. Invesco Ltd. now owns 1,699,756 shares of the biopharmaceutical company's stock valued at $71,509,000 after purchasing an additional 25,487 shares during the period. Vestal Point Capital LP grew its stake in shares of Ultragenyx Pharmaceutical by 100.0% in the 4th quarter. Vestal Point Capital LP now owns 1,500,000 shares of the biopharmaceutical company's stock valued at $63,105,000 after purchasing an additional 750,000 shares during the period. Alyeska Investment Group L.P. grew its stake in shares of Ultragenyx Pharmaceutical by 23.1% in the 4th quarter. Alyeska Investment Group L.P. now owns 1,439,740 shares of the biopharmaceutical company's stock valued at $60,570,000 after purchasing an additional 269,733 shares during the period. Finally, Point72 Asset Management L.P. grew its stake in shares of Ultragenyx Pharmaceutical by 81.0% in the 4th quarter. Point72 Asset Management L.P. now owns 1,182,877 shares of the biopharmaceutical company's stock valued at $49,764,000 after purchasing an additional 529,217 shares during the period. 97.67% of the stock is currently owned by institutional investors.

Insider Activity at Ultragenyx Pharmaceutical

In other news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the business's stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $37.39, for a total value of $89,922.95. Following the transaction, the director directly owned 15,344 shares of the company's stock, valued at $573,712.16. The trade was a 13.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 5.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

RARE has been the topic of several research analyst reports. Morgan Stanley decreased their price objective on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a research note on Monday, July 14th. William Blair initiated coverage on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, May 28th. They set an "outperform" rating and a $65.00 price objective on the stock. HC Wainwright raised shares of Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 price objective on the stock in a research note on Monday, July 28th. Canaccord Genuity Group decreased their price objective on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating on the stock in a report on Friday. Finally, Wells Fargo & Company decreased their price objective on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating on the stock in a report on Thursday, July 10th. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $81.50.

Ultragenyx Pharmaceutical Trading Up 2.6%

Ultragenyx Pharmaceutical stock traded up $0.72 during mid-day trading on Tuesday, reaching $28.11. The company had a trading volume of 1,128,461 shares, compared to its average volume of 2,487,268. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $25.81 and a fifty-two week high of $60.37. The company has a market cap of $2.71 billion, a P/E ratio of -5.08 and a beta of 0.25. The business has a fifty day simple moving average of $32.98 and a 200 day simple moving average of $36.50.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The business had revenue of $166.50 million for the quarter, compared to the consensus estimate of $161.37 million. During the same period last year, the company earned ($1.52) EPS. The firm's revenue was up 13.2% compared to the same quarter last year. Research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.